deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT04594369

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study

Sponsor: Insmed Incorporated

Conditions Non-Cystic Fibrosis Bronchiectasis
Interventions Brensocatib 10 mg Brensocatib 25 mg Placebo
Updated 35 times since 2020 Last updated: Nov 28, 2025 Started: Dec 1, 2020 Primary completion: Oct 28, 2024 Completion: Oct 28, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-Cystic Fibrosis Bronchiectasis, this trial is completed. The trial is conducted by Insmed Incorporated and has accumulated 35 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

35 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Jan 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 30 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  6. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  7. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  8. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  10. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  11. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  12. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  13. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  14. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  15. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  16. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  17. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  18. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  19. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  20. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  21. Jan 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  22. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  23. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  24. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  25. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  26. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  27. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  28. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  29. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  30. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Insmed Incorporated
Data source: Insmed Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Adelaide, Australia , Alexandroupoli, Greece , Alkmaar, Netherlands , Amiens, France , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Ansan-si, South Korea , Arnhem, Netherlands and 308 more locations